- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061306
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study (CDGEMM)
Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) Study
Study Overview
Status
Conditions
Detailed Description
The CDGEMM study will address genomic, environmental, microbiome, and metabolomic factors that could affect the development of CD.
Genomic: The investigators will study children who have a first degree relative with celiac disease so that we can understand how their genes may contribute to whether they develop CD or not. Scientists and doctors are already aware of one group of genes, called the HLA DQ2 and DQ8 genes, which are involved in the development of CD. These genes are necessary for development of CD, but cannot alone predict who will develop the disease. The investigators hope that the CDGEMM study will help to not only learn more about these specific genes, but also identify other genes that could make it easier to predict who will develop CD.
Environmental: When infants enroll, the investigators will record information about their environment including whether they were born vaginally or by Cesarean section and whether they were given antibiotics. Over time, the investigators will also consider other parts of the infant's medical history including feeding modality (breastfeeding versus formula feeding), illnesses, infections, and growth to understand if any of this information is related to CD development. Since the investigators will follow infants until they reach 5 years of age, the investigators will update this information every six months to understand how changes might affect if the child develops CD or not.
Microbiome: Our gut, compromised of the small and large intestine, contains many types of bacteria. These bacteria that live in the gut normally help to break down and digest food, provide our bodies with energy, and make vitamins that our bodies need. This diverse community of bacteria is called the gut microbiome. A main goal of the CDGEMM study is to understand how the microbiome is affected by other factors, like foods or antibiotic drugs, and how this may affect the development of CD. It is possible that learning about the types of bacteria living in the gut before and after disease development may help us predict who will develop CD before it happens.
Metabolomic: The processes that occur in our gut, such as the digestion of foods and production of vitamins, create products that are called metabolites. The specific metabolites that we produce differ from person to person and depend on many factors, including the genes that we have, the members of the gut microbiome, and the foods that we eat. We will study the infant's unique metabolomic profile (metabolites that the infant produces) to understand if there is a specific profile associated with CD.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00185
- Recruiting
- University of Roma La Sapienza
-
Contact:
- Francesco Valitutti, MD
- Email: cdgemmita@mgh.harvard.edu
-
Principal Investigator:
- Salvatore Cucchiara, MD PhD
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital for Children
-
Contact:
- Tori Kenyon
- Phone Number: 617-643-4366
- Email: cdgemm@mgh.harvard.edu
-
Principal Investigator:
- Alessio Fasano, MD
-
Sub-Investigator:
- Maureen M. Leonard, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Newborns and infants less than 6 months of age who have not been introduced to solid foods (exclusive breast milk or formula diet)
- First-degree relatives of patients affected with biopsy-proven CD
Exclusion Criteria:
- Infants older than 6 months of age
- Inability or unwillingness of legal guardian/representative to give written informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Infants with a first-degree relative with celiac disease
Infants who have a first-degree relative diagnosed with celiac disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in composition of the microbiota of CD in at-risk infants using culture-independent high-throughput sequence analysis of the 16S rRNA genes using the Illumina sequencing platform.
Time Frame: Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity
|
We will use stool samples collected over time to survey the microbial community in order to establish microbiota patterns associated with CD autoimmunity.
|
Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gut permeability measured by serum zonulin levels and loss of gluten tolerance measured by increased expression of pro-inflammatory cytokines and appearance of anti-tTg antibodies.
Time Frame: Every six months until age 3. Every year thereafter until age 5.
|
We anticipate that timing of gluten introduction in the infant's diet will influence shift in enterotype and metatranscriptome profile with subsequent increase in gut permeability and loss of gluten tolerance.
|
Every six months until age 3. Every year thereafter until age 5.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the characterization of infants' metabotypes (metabolomes) using an established and proven commercial metabolomics technology platform by Metabolon, Inc.
Time Frame: Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity
|
Our preliminary data suggest that individual metabolomic phenotypes (which are a result of gene-diet-gut microbiome interactions) can help define specific enterotypes associated to loss of gluten tolerance in infants genetically at risk of CD.
|
Every six months through five years of age with specific focus on time of gluten introduction, time at which gluten tolerance is lost and autoimmunity develops (if applicable), and parallel time points in infants who do not go on to develop autoimmunity
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Maureen M. Leonard, MD, Massachusetts General Hospital
- Principal Investigator: Alessio Fasano, MD, Massachusetts General Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013P001965
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
University of PalermoCompletedNot-celiac Gluten (Wheat) SensitivityItaly
-
University of PalermoRecruiting
-
University of PalermoCompletedNot-celiac Gluten SensitivityItaly
-
ASST Fatebenefratelli SaccoNot yet recruiting
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitationCeliac Disease in ChildrenNetherlands